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INTRODUCTION 
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Iron is an essential micro-nutrient. Cellular iron is mainly utilized 
for synthesis of heme, iron-sulphur clusters and ferritin. Ferritin is 
the storage form of iron in human beings. Iron-sulphur clusters 
synthesized from cellular iron are found in proteins involved in 
electron transport chain (Longo et al. 2011). Iron requirements vary 
among individuals during development (Longo et al. 2011). Excess 
iron produces free radicals and cause tissue damage. On the other 
hand, iron-deficient cells were not able to meet the energy 
requirements due to reduction in electron transport chain proteins. 
In iron deficient erythroid cells hemoglobin synthesis is also 
impaired (Longo et al. 2011).  
  
Pregnancy is a normal physiological condition with increased 
demands for iron. Anemia is more common during pregnancy in 
most of the developing countries. The National Family Health 
Survey-3 (NFHS-3), has estimated the prevalence of anemia in 
pregnancy to be about 57.9 % in India (Bhat et al, 2007)  
 
Hepcidin is the principal regulator of iron homeostasis in the body 
(Murray et al. 2012).  It is mainly synthesized in hepatocytes. It 
decreases iron efflux from the cell by internalization and 
degradation of the iron efflux protein, ferroportin (Murray et al. 
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2012). Hepcidin maintains systemic iron levels and provides 
adequate iron to the cells when demand for iron increases. 
  
As pregnancy progresses, there is an increased iron demand to 
provide adequate iron for development of the fetus. Hepcidin, which 
regulates systemic iron levels, has been found  to be reduced during 
the second and third trimesters of pregnancy; this ensures adequate 
iron for fetal development (Finkenstedt et al. 2012). Animal studies 
have shown  decreases in hepcidin levels through  pregnancy and 
increases in the postpartum period (Millard et al. 2004). There is 
little published data in this regard in humans.   
 
Evidence from previous studies has shown that levels of hepcidin 
and ferritin significantly decreased during pregnancy and also 
negative correlation has been shown between hepcidin and 
erythropoietin, a marker for increased iron demand (Finkenstedt et 
al. 2012). This shows the depletion of iron stores was mainly to 
provide more iron for fetal development (Finkenstedt et al. 2012).  In 
the present study, we estimated serum levels of hepcidin in women 
with uncomplicated pregnancies and correlated this with 
hemoglobin and ferritin levels in these subjects. This study was 
done as an attempt to understand better the changes that occur in 
iron-related proteins in pregnancy.  
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         Serum hepcidin levels in normal pregnancy 
 
Background of the study 
Systemic iron levels are regulated by hepcidin. Evidence from 
animal studies shows that hepcidin levels were reduced during 
pregnancy, to provide adequate iron for fetal development, and 
raised in the post-partum period. Literature in this area on 
human subjects is very limited, with no data available from India 
 
 
Aim of the study 
The aim of the study was to determine serum hepcidin levels in 
women with uncomplicated pregnancies.  
 
Materials and methods 
Thirty healthy pregnant women (10 in each trimester), without any 
pregnancy-associated complications, were chosen as subjects. They 
were recruited from the antenatal clinic of the Community Health 
and Development (CHAD) hospital, at Christian Medical College 
(CMC), Vellore. Ten healthy age-matched non-pregnant females 
were selected as control subjects. The study protocol was approved 
by the Institutional Review Board of CMC, Vellore. Informed consent 
was obtained to collect 10ml of blood from each subject at the time 
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of recruitment into the study. Levels of serum hepcidin, ferritin, C-
reactive protein and hematological parameters were estimated in 
each sample.  Data were analysed by appropriate statistical tests, 
using SPSS, version 16. A p value of <0.05 was considered to be 
statistically significant. 
 
Results 
Serum hepcidin and hemoglobin levels tended to decrease as 
pregnancy progressed, but the changes were not statistically 
significant in the case of hepcidin. In the case of hemoglobin, levels 
in the third trimester were significantly lower than those in control 
subjects. Hemoglobin, serum ferritin and haematocrit levels showed 
significant positive correlations with one another. Hepcidin levels 
were not significantly correlated with any of the parameters 
measured.  
 
Conclusion 
Serum hepcidin levels tended to decrease with increasing 
gestational age, but the decreases seen were not statistically 
significant. Since the sample size in this study was small, further 
studies in this area are warranted to confirm these findings and to 
further study the complex biological relationships between hepcidin 
and iron-related proteins, in pregnancy. 
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Iron mainly occurs in two ionic forms, Fe2+ (bio available form) and 
Fe3+ (storage form). Iron-containing proteins are involved in various 
functions, such as transport of oxygen, intermediary metabolism 
and regulation of transcription (Longo et al. 2011). Hemoproteins in 
the human body that contain iron include hemoglobin, myoglobin 
and cytochromes (Murray et al. 2012). 
 
The total body iron levels are about 3-4g in a normal adult male  
and 2-3g in a normal adult female (Ross et al,2014). In adult 
females, the total body iron content is less than that in males. Iron 
requirements increase in premenopausal women due to menstrual 
losses (Murray et al. 2012).  Iron loss is about 1mg/day.  Iron levels 
are maintained by absorption of  about the same amount per day 
(Murray et al. 2012).  
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IRON DISTRIBUTION IN THE BODY 
 
Hemoproteins   
 
 
Adult male 
 Iron concentration  
 in mg  
Adult female 
Iron concentration  
 in mg 
 
Hemoglobin   
Myoglobin/Enzymes 
Transferrin 
Ferritin 
   
 2500 
  500 
3 
600-1000 
  
 1700 
   300 
      3 
0-300 
 
 
 
 
DIETARY IRON 
 
Dietary iron mainly occurs in two forms, heme iron and non-heme 
iron. Heme iron is obtained from food such as red meat, fish, and 
poultry. Non- heme iron is obtained from plant sources (Ross et al, 
2014).The bioavailability of heme iron is greater than that of non-
heme iron ( Ross et al, 2014). The absorption of iron is influenced by 
iron stores in the body. When body iron stores are low, the 
absorption of iron is increased; when iron stores are high, the 
Source: Harrison’s Principles of Internal Medicine, 18th Edition.  
McGraw Hill; 2011; chapter 103; Page 1552 
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absorption of iron is less (Theil EC, 2004). Vitamin C reduces ferric 
iron in the diet to the ferrous form of iron, which is the bio-available 
form. Vitamin C therefore  increases iron absorption (Siegenberg et 
al. 1991). Phytates inhibit the absorption of non-heme iron 
(Siegenberg et al. 1991). Calcium inhibits absorption of both heme 
and non-heme iron (Hallberg et al. 1991).  
 
IRON IN ENTEROCYTES 
 
Non-heme iron absorption from the diet 
 
Dietary non-heme iron is absorbed in the proximal part of the small 
intestine (Longo et al. 2011). It is regulated at the level of 
absorption, as the body is not able to eliminate any excess of iron 
that is absorbed (Ross et al.2014).  Most of the dietary non-heme 
iron is in the form of ferric iron (Fe 3+) (Murray et al. 2012).  At 
physiological pH and in the presence of oxygen, iron exists most 
commonly as a highly insoluble ferric (Fe3+) form. The iron transport 
system in the body is able to take up unstable ferrous (Fe2+) ion 
(Gunshin et al. 1997).  In the enterocytes, the first step for 
absorption of iron involves reduction of insoluble ferric iron (Fe3+) to 
soluble ferrous iron (Fe2+). This is effected by a brush-border ferri-
reductase (Raja et al 1992; Riedel et al. 1995; McKie et al. 2001). In 
mammals, the ferrireductase activity is observed in three main 
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groups of proteins, they are duodenal cytochrome b (Dcytb/cybrd1), 
cytochrome b561 homologues and the STEAP (six transmembrane 
epithelial antigen of prostate) family of metallo reductases (Vargas et 
al. 2003) 
 
Duodenal cytochrome b (Dcytb) 
 
Dcytb (Cybrd1) is a plasma membrane protein with ferri-reductase 
activity. It is expressed in the duodenal brush border and RBC 
membranes. It is a member of the cytochrome b561 family (McKie et 
al. 2001).  It is an iron-regulated protein that  has 286 amino acids 
and six transmembrane domains ( McKie et al. 2001).  In response 
to iron deficiency and hypoxia, the iron- regulated Dcytb mRNA and 
protein are rapidly induced ( McKie et al. 2001).  
 
Ferrous iron, once formed by the action of Dcytb, enters enterocytes 
through divalent metal transporter 1 (DMT1) (Gunshin et al. 1997; 
Fleming et al. 1997), which is located on the apical surface of 
enterocytes. 
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Divalent metal transporter 1 (DMT1) 
 
DMT1 is a member of the 'natural-resistance-associated 
macrophage protein' (Nramp) family. DMT1 is also called natural 
resistance-associated macrophage protein 2 (NRAMP2) or divalent 
cation transporter 1 (DCT1) or SLC11A2 (solute carrier family 11 
member 2) (Longo et al. 2011). It is a 561-amino-acid protein, with 
12 membrane-spanning domains. It is expressed ubiquitously. In 
the proximal duodenum, it mediates active transport of divalent 
metals such as Fe2+, Cu2+, Mg2+ (Gunshin et al. 1997). The active 
transport of metals is proton-coupled and mainly depends on the 
cell membrane potential (Gunshin et al. 1997). 
 
Iron  absorbed  from the proximal duodenum (both heme and non-
heme iron) forms a labile iron pool in enterocytes. When the body 
has sufficient iron, this pool is utilized for biosynthesis of ferritin 
and iron-sulphur clusters.  
 
Iron in the ferrous form (Fe2+) is exported from enterocytes by 
ferroportin (Fpn), which is located on the baso-lateral surface of 
enterocytes ( McKie et al. 2000; Abboud et al 2000;  Donovan et al. 
2000). 
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Ferroportin (Fpn) 
 
Ferroportin is a member of the metal transport protein 1 family of 
protein (McKie et al. 2000; Abboud et al. 2000). It is also called 
SLC40A1 (solute carrier family 40 member 1) or IREG1 (iron-
regulated transporter 1) or MTP1 (metal transport protein 1) 
(Abboud et al. 2000). It is made up of 581 amino acids, with 10-12 
transmembrane domains (Donovan et al. 2005). It is highly 
expressed in macrophages, duodenal mucosal cells, hepatocytes, 
Kupffer cells and placental syncytiotrophoblast cells (Abboud et al. 
2000). The ferroportin gene is highly regulated. This regulation is 
mediated by iron-regulatory proteins (IRPs). These proteins binds to 
iron-responsive elements (IRE) on the 5’ untranslated region (UTR) 
of ferroportin mRNA (Sanchez et al. 2006) and cause translational 
repression of ferroportin in iron deficient cell. Transcriptional 
activation of  ferroportin mediated by the activation of heme 
oxygenase-1 (HO-1), occurs in macrophages following 
erythrophagocytosis (Delaby et al. 2008).In the duodenum, 
ferroportin is involved in the efflux of iron from enterocytes to blood 
(Murray et al. 2012).  
 
Ferroportin is also the receptor for hepcidin, the major regulatory 
hormone in iron metabolism (Nemeth, et al. 2004). Hepcidin binds 
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to ferroportin and cause its endocytosis and degradation (Nemeth, 
et al. 2004) when systemic iron levels are adequate. 
 
Hephaestin 
 
The ferrous iron that is exported by ferroportin is converted back to 
ferric iron by hephaestin. This is a protein bound to the baso-lateral 
membrane of enterocytes (Domenico et al. 2007; Murray et al. 2012; 
Vulpe et al. 1999; Chen et al. 2004). It has ferroxidase activity 
(Vulpe et al. 1999; Roeser et al. 1970) that converts ferrous iron to 
ferric iron. Copper is required for structural and enzymatic activity 
of hephaestin (Syed et al. 2002; Vulpe et al. 1999; Chen et al. 2004). 
The ferric iron released from the enterocytes binds to transferrin, 
which transports  it to target cells in the body (Schade et al. 1946). 
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Heme iron absorption from the diet 
 
Heme iron is absorbed in the proximal part of the small intestine. It 
is thought to be absorbed via a heme transporter, heme carrier 
protein 1 (HCP 1) (Latunde-Dada et al. 2006).  
 
Heme carrier protein 1 (HCP 1) 
 
 HCP 1 belongs to the family of proton-coupled transporter/major 
facilitator super- family ( Blanc L et al,  2012). HCP 1 is also called 
as proton coupled folate transporter (PCFT) ( Blanc L et al,  2012). 
HCP-1/PCFT is mainly a folate transporter and low-affinity heme 
transporter that is regulated by cellular iron levels (Laftah et al. 
2009). HCP-1 undergoes post-translational regulation, by  iron 
levels in the duodenum (Latunde-Dada et al. 2006). Iron deficiency 
with reduced iron levels causes localisation of HCP-1 on the apical 
surface of enterocytes. Excess of iron results in localization of HCP-
1 in the cytoplasm ( Blanc L et al,  2012) 
 
 Absorbed heme iron is acted upon by hemoxygenase-1 (HO-1) in 
the enterocytes to release iron (Raffin et al. 1974). Fe2+ iron released 
by this enzyme adds it to the labile iron pool. Labile iron pool serves 
as a source for synthesis of ferritin (storage form), iron-sulphur 
cluster and heme proteins. Heme iron is exported out of enterocytes 
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via feline leukemia virus subgroup C cellular receptor 1 (FLVCR 1) 
(Quigley et al. 2004). 
 
Feline leukemia virus subgroup C cellular receptor 1  
(FLVCR 1) 
 
FLVCR exports cytoplasmic heme. It is important for erythroid 
differentiation (Keel et al. 2008). FLVCR is expressed more at sites 
where high heme flux is needed. FLVCR 1 is also expressed in 
various tissues such as the liver, erythropoietic progenitor cells, 
duodenum, kidney, placenta and brain (Keel et al. 2008).  
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Figure1- Absorption of heme and non heme iron in duodenal    
enterocytes 
 
 
 
 
 
 
18 
 
IRON IN CIRCULATION 
 
Ferric iron released from enterocytes is taken up by transferrin (Tf), 
(Schade et al. 1946), the major iron transporter in circulation.  
 
Transferrin 
 
Transferrin is a glycoprotein synthesized in the liver (Longo et al. 
2011). Human transferrin contains 678 amino acid residues and 
two asparagine-linked glycans. It contains two iron-binding sites for 
ferric iron (Aisen et al. 1966). Normally, one-third of iron binding 
sites in transferrin are bound to iron, resulting in transferrin 
saturation levels of 30-50% (Longo et al. 2011) . The half-life of 
transferrin-bound iron is about 60-90 minutes. This iron taken up 
by cells are utilized or stored as ferritin (Ross et al. 2014). 
Transferrin with ferric (Fe3+) iron bound to it  is called holo-
transferrin (Tf) (Murray et al. 2012). Cells take up holo-transferrin 
via the transferrin receptor (TfR) (Murray et al. 2012).  
 
Non-transferrin-bound iron (NTBI) 
 
When serum iron levels exceed the iron-binding capacity of 
transferrin, iron in circulation forms non-transferrin-bound iron 
(NTBI) (Barisani et al. 1995). 
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Transferrin receptors 
 
Transferrin receptors are a cell surface glycoprotein present in all 
cells, except mature red blood cells (Ross et al. 2014). TfR is highly 
expressed in erythroid marrow , placenta (Wada et al. 1979) and the 
liver (Gatter et al. 1983). The transferrin receptor is a disulfide-
linked homodimer. Each monomer has 760 amino acids and has a 
short cytoplasmic N-terminal region, a single transmembrane 
domain and a glycosylated extracellular region. The ligand-binding 
domain is extracellular. The intracellular segment has a 
phosphorylation site activated by protein kinase C (Davis et al. 
1986).  
 
Transferrin receptors are of two types, TfR1 and TfR2 (Kawabata et 
al. 1999). TfR1 is mainly involved in cellular uptake of transferrin 
bound iron. TfR1 has high affinity for transferrin bound iron when 
compared to TfR 2α (Kawabata et al. 2001; Ikuta et al. 2010). TfR2 
is highly expressed on hepatic cells and erythroblasts (Kawabata et 
al. 2001). It  has two isoforms TfR2α and TfR2β (Kawabata et al. 
1999).TfR2α is a transmembrane protein whereas TfR2β is an 
intracellular protein (Kawabata et al. 1999).  
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Cellular uptake of iron (transferrin cycle) 
 
The transferrin cycle occurs during cellular uptake of transferrin-
bound iron (Murray et al. 2012). Cellular uptake occurs by the 
process of receptor-mediated endocytosis (Ross et al. 2014). When 
holo-transferrin binds to TfR, the Tf-TfR complex is endocytosed. 
The interior of the endosome formed is acidic. Due to the low pH, 
the ferric iron is released from the Tf-TfR complex. This iron is then 
reduced to its ferrous form by STEAP3 (six transmembrane 
epithelial antigen of prostate family member-3) ( McKie et al. 2005). 
STEAP3 is a NADPH-dependant ferri-reductase (Ohgami et al. 
2005). The ferrous iron formed exits the endosome through DMT1 in 
the endosomal membrane and enters the cell cytosol. Transferrin 
and transferrin receptor are recycled back to the cell surface for 
further uptake of iron. The transferrin cycle occurs in a cell about 
10-20 times a day (Murray et al. 2012). 
 
Soluble transferrin receptor (sTfR) 
 
Soluble transferrin receptor (sTfR) is a proteolytic product of TfR1, 
which circulates in plasma (Ross et al. 2014). Proteolysis occurs at 
surface of the receptor forming sTfR, which is released by exocytosis 
into the blood (Beguin 2003).  About 80% iron in circulation is 
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utilized by erythroid precursor cells (Longo et al. 2011). The 
circulating sTfR is directly proportional to expression of cellular TfR 
(Beguin 2003). The quantity of transferrin receptor expressed on a 
cell surface depends on its need for iron. sTfR is increased in iron-
deficiency anemia (Longo et al. 2011). sTfR is a good marker of 
maternal iron status and fetal demand and is increased during the 
course of normal pregnancy (Choi et al. 2000). 
 
                  Figure 2:  Transferrin cycle 
 
 
 
 
Source:  Mckie et al, 2005 
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Uptake of non-transferrin-bound iron (NTBI) 
 
Uptake of non-transferrin-bound iron by cells causes iron toxicity 
(Batey et al. 1981). The process of NTBI uptake in liver occurs 
mainly via DMT1 and Zrt- and Irt-like protein, 14 (ZIP 14), a zinc 
transporter (Arias et al. 2011). The transporters involved in such 
uptake in cardiac myocytes have been shown to be L-type of Ca2+ 
channels (Oudit et al. 2003) and transient receptor potential cation 
channel (TRPC 6) (Mwanjewe et al. 2000). The toxicity due to uptake 
of NTBI occurs in hepatocytes, cardiac myocytes and endocrine 
tissues (Andrews NC et al. 2007).  
  
Regulation of cellular iron homeostasis 
 
Increased free iron in the cell leads to oxidative damage (Murray et 
al. 2012). Iron regulatory proteins, IRP1 and IRP2, are cytosolic 
RNA-binding proteins that help maintain iron level inside the cell. 
IRP1 and IRP2 regulate post transcriptional expression of mRNA of 
proteins involved in iron utilization (Theil EC 1993).  Iron  
responsive elements (IRE ) are located in the 5’ untranslated region 
(UTR) in the mRNA of ferritin (Leibold et al. 1988), mitochondrial 
aconitase (Zheng et al. 1992) and erythroid δ-aminolevulinic acid 
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synthase (δ-ALAS) (Dandekar et al. 1991). IRE are also located at 3’ 
end of mRNA of TfR1 and DMT1 (Dupic et al. 2002).  
 
In iron deficiency, IRP is involved in translational control by binding 
to IRE at the 5’UTR of ferritin and ferroportin, to reduce synthesis 
by translational repression (Ross et al. 2014). Binding of IRP to 3’ 
UTR of TfR1 and DMT1 increase the mRNA stability to enhance iron 
transport (Ross et al. 2014). 
 
Iron regulatory protein 1 (IRP 1) 
 
IRP 1, an iron sulphur cluster protein (Rouault et al. 1991) has two 
functions. In iron- replete cells, it functions as cytoplasmic 
aconitase (that converts citrate to isocitrate) (Rouault et al. 1992).  
Both IRP 1 and 2 have  equal affinity (Rouault et al. 1991) for IRE.  
In iron-deficient cells, binding of IRP1 to IRE-containing TfR1 mRNA 
at the 3’ UTR stabilizes TfR1 mRNA (Müllner et al, 1989; Casey et al. 
1989). Binding of IRP to the 5’ UTR of ferroportin and ferritin, cause 
translational repression (Goossen et al. 1990) . 
 
Iron regulatory protein 2 (IRP 2) 
 
IRP2 is an iron-sulphur cluster protein (Rouault et al. 1992). It 
functions only as RNA-binding protein. When iron is scarce, IRP2 
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binds to IRE; when intracellular iron levels are increased, IRP2 
undergoes proteosomal degradation. 
 
Figure 3:  Regulation at cellular level 
 
 
                             
                       Source: Hentze et al, 2010. 
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IRON IN MACROPHAGES 
 
Most of the iron in erythrocytes is recycled from the monocytes and 
macrophages of the reticuloendothelial system; this is 20 times 
more than the amount absorbed from the intestine  (Andrews NC 
1999). 
 
The reticulo-endothelial system recycles iron (Andrews NC 1999). 
Iron enters the macrophages by three mechanisms (Evstatiev R et 
al.2012) 
 
1. Phagocytosis of senescent erythrocytes 
2.  Heme uptake 
3. TfR1-mediated uptake of holo-transferrin 
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                  Figure 4: Iron in macrophages 
 
 
 
 
Phagocytosis of senescent erythrocytes in 
macrophages 
 
Senescent erythrocytes are taken up by phagocytosis of 
macrophages. As a result of phagocytic activity, heme iron is 
released from the erythrocytes. Extracellular free heme is toxic 
because of its oxidant  property (Ross et al. 2014). Heme is then 
Source:  Evstatiev R et al, 2012. 
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acted on by heme oxygenase-1 (Raffin et al. 1974). The iron released 
by this enzyme adds to the labile iron pool. This pool is maintained 
in at physiological levels by IRP-dependent translational control of 
ferritin and transferrin receptor. IRP-independent ferritin 
degradation also occurs to prevent toxic effects (Konijn et al. 1999). 
Some of the heme iron is exported from macrophages via feline 
leukemia virus subgroup C cellular receptor 1 (FLVCR 1) (Quigley et 
al. 2004). 
 
Heme uptake by macrophages 
 
The forms in which heme is taken up by macrophages are 
hemoglobin and extracellular heme, which is produced as a result of 
haemorrhage, hemolysis or other types of cell damage. Heme in the 
form of hemoglobin is taken up by macrophages via a heme-
scavenging receptor, CD163, as hemoglobin-haptoglobin complexes 
(Kristiansen et al. 2001). CD163 is located most commonly in 
phagocytic macrophages (Kristiansen et al. 2001).   
 
Extracellular heme binds to hemopexin, a β1-glycoprotein with high 
affinity for heme (Hrkal,et al. 1974). The heme-hemopexin complex 
is taken up by macrophages through LRP/ CD91 (LRP-low density 
lipoprotein receptor-related protein). LRP/ CD91, a α2-macroglobin 
receptor, is expressed in macrophages, hepatocytes, adipocytes, 
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neurons and syncytiotrophoblasts (Moestrup et al. 1992). Heme-
hemopexin complex and hemoglobin-haptoglobin complex, along 
with the receptor complex, are endocytosed. In the lysosome, the 
ligand gets degraded to release heme. The receptors are recycled 
back to the surface (Hvidberg et al. 2005).  
 
                    Figure 5: Heme uptake in macrophages 
 
 
 
 
 
 
 
 
    Source: Hvidberg V et al, 2005 
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TfR1-mediated uptake of transferrin by macrophages 
 
TfR1 mediated uptake in macrophages occurs via receptor-mediated 
endocytosis (Figure 4). 
 
 Ferrous iron released from heme, transferrin and senescent 
erythrocytes forms the labile iron pool. Iron from labile iron pool is 
used for ferritin synthesis or is exported via ferroportin. 
Ceruloplasmin reduces ferric  Fe3+ to ferric Fe2+ (Roeser et al. 1970), 
which then binds to transferrin which transports iron to target 
tissues. The process by which ferritin is released from macrophage 
is still unclear (Barton et al. 1999) 
 
IRON IN ERYTHROBLAST 
                           
Erythroblast take up a large quantity of iron (approximately 80%) 
for hemoglobin synthesis (Longo et al. 2011). Iron enters 
erythroblast through TfR1 (Longo et al. 2011). STEAP3, an 
endosomal ferrireductase mainly found in erythroid cells.  (Ohgami 
et al.2005). 
 
Ferrous iron is utilized for hemoglobin synthesis. Excess iron can be 
stored in the cell as ferritin (Longo et al. 2011). FLVCR  expressed in 
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erythropoietic progenitor cells exports out hemoprotein (Keel et al. 
2008).  
      
Figure 6: Iron in erythroblast 
 
 
                        Source: Lipinski P et al, 2013 
 
IRON IN HEPATOCYTES 
 
Ferritin is a ubiquitous protein and the main storage form of iron 
(Murray et al. 2012). Iron is stored as ferritin mainly in hepatocytes, 
macrophages in the spleen and bone marrow (Worwood 1979).   
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Ferritin 
 
Mammalian ferritin is a large protein. It is about 450kDa in size and 
made up of 24 units of apoferritin monomers to form a spherical 
particle. It encloses a core of ferric-hydroxy-phosphate, which can 
hold up to 4,000 atoms of iron as Fe3+ (Arosio et al. 1978).  It has 
two subunits heavy (H-chain) and light chains (L-chain), which 
contain 4000 atoms of iron (Harrison et al. 1996). The proportion of 
H and L subunits varies in different tissues. The L form 
predominates in the liver and spleen and the H form predominates 
in the heart and kidney (Torti et al. 2002).  
 
Ferritin is a soluble protein. When degraded, it accumulates in 
lysosomes as insoluble haemosiderin. Both ferritin and 
haemosiderin are storage forms of iron (Theil EC 1990). 
Circulating ferritin is mostly in the L form; it does not contain iron 
(Theil EC 1990). H-ferritin subunits have an active ferroxidase site 
in human (Theil EC 1990). 
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                          Hepcidin 
 
Hepcidin, the major regulator of systemic iron is produced in liver 
as a pre-propeptide, with 84 amino acids. It contains a 24 amino 
acid N-terminal endoplasmic reticulum-targeting signal sequence 
(Hunter et al. 2002). The 60-amino acid pro-hormone is produced 
after cleavage of N-terminal endoplasmic reticulum-targeting signal 
sequence(Park et al. 2001). The pro-hormone has  pro-protein 
convertase activity that cleaves it and produces mature hepcidin 
with 25, 20 and 22 amino acids (Pigeon et al. 2001; Park et al. 
2001; Krause et al. 2000). The active form is hepcidin with 25 
amino acids (Park et al. 2001; Krause et al. 2000). Hepcidin in 
circulation is bound to α2-macroglobin (Peslova et al. 2009). It is 
excreted by the kidney (Park et al. 2001; Krause et al. 2000).  
 
Hepcidin has eight cysteine residues with four disulphide cross-
links and a beta hairpin structure (Park et al. 2001). It has a highly 
conserved N-terminal arm, essential for the hormone activity (Park 
et al. 2001).  Hepcidin regulates iron homeostasis by binding to 
ferroportin. Ferroportin is then internalized and degraded (Nemeth 
et al. 2004). Hepcidin is the protein mainly involved in the 
regulation of iron at the level of intestinal absorption, recycling of 
iron in macrophages and also in mobilization of iron from hepatic 
stores ( Nemeth et al. 2004). 
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Regulation of hepcidin 
 
The transcription of hepcidin, which regulates systemic iron 
balance, is mainly controlled by the following factors: 
                      1. Transferrin saturation 
                      2. Liver iron 
                      3. Erythroid activity 
                      4. Inflammation 
                      5. Hypoxia 
 
Hepcidin is up-regulated by iron over-load and inflammation and 
down-regulated by erythropoiesis and hypoxia (Nemeth  et al. 2004; 
Pigeon et al. 2001; Nicolas et al. 2002).  
 
Hfe-TfR2 pathway in regulation of hepcidin  
 
The Hfe gene is an atypical major histocompatibility complex class-1 
like molecule. The protein, when mutated, leads to classical 
hereditary hemochromatosis (Goswami et al. 2006). Hfe is 
associated with β2-microglobulin.  It  is expressed on the cell 
surface, associated with transferrin receptor 1(TfR 1) (Feder et al. 
1998). The transferrin receptor 1 has binding sites for transferrin 
and Hfe. Transferrin competes with Hfe for binding sites on TfR1, as 
binding sites of both transferrin and Hfe overlaps (West et al. 2001). 
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Hfe can also bind to transferrin receptor 2 (TfR2) (Goswami et al. 
2006). When the concentration of holo-transferrin in blood is 
increased, it displace Hfe from TfR1 and favours Hfe-TfR2 
interaction. Hfe-TfR2 binding causes activation of p38-MAPK 
(microtubule associated protein kinase- extracellular signal-
regulated kinase) signalling cascade (Wallace et al. 2009). This 
promotes hepcidin transcription (Goswami et al. 2006).  
 
           Figure 7: Role of Hfe-TfR2 in hepcidin transcription 
 
 
 
 
Source: Goswami et al, 2006. 
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BMP-SMAD signalling pathway for hepcidin regulation 
 
The BMP receptor complexes are serine/ threonine kinase receptors. 
The BMP receptor complex is composed of type I (BMPRI) and type II 
(BMPRII). When a ligand binds to the receptor complex, BMPRII 
phosphorylates BMPRI which then propagates the signal to the 
cytosolic transcription factors SMAD 1/5/8 (receptor-activated 
SMAD, R-SMAD). Increase in hepcidin expression through a 
number of BMPR ligands such as BMP2, BMP5, BMP6, BMP7 and 
BMP9 is known (Wang et al. 2005). Among these BMPs, the key 
regulator of hepcidin expression is BMP6 (Andriopoulos et al. 2009). 
BMP 6 is produced from non-parenchymal cells in the liver in 
response to increase intracellular iron. 
 
The BMP binds to BMP receptors to induce phosphorylation of 
receptor-activated SMAD (R-SMAD). SMAD protein is a human 
homolog of Drosophila melanogaster MAD protein (Mothers-Against-
Decapentaplegic) and Caenorhabditis elegans SMA gene. The 
activation of R-SMAD causes activation of transcriptional complexes 
by SMAD4 by dimerization with SMAD4 and translocates into the 
nucleus causing hepcidin induction  (Wang et al. 2005).  
 
Hemojuvelin (HJV) is a glycophosphatidyl inositol (GPI)-anchored 
protein, which acts as a bone morphogenetic protein (BMP) co-
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receptor. Hemojuvelin also occurs as two isoforms- membrane 
bound and soluble form. HJV acts through BMP-SMAD signalling 
for regulation of iron (Babitt et al. 2006). Both HJV and Hfe activate 
hepcidin transcription via R-SMAD phosphorylation and SMAD4  
(Corradini et al. 2009; Kautz et al. 2009). Soluble hemojuvelin 
(sHJV) is a negative regulator of hepcidin mRNA transcription (Lin 
et al. 2005).  
 
Figure 8: Model for hepcidin transcription (BMP-SMAD pathway) 
 
 
                                 Source: Zhao et al .2013   
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2. GDF 15 (growth differentiation factor) and TWG 1 
(twisted gastrulation factor) in regulation of hepcidin 
 
The down-regulation of hepcidin by erythropoiesis is mediated by 
factors that are currently not definitively known. Erythroferrone 
(ERFE), GDF 15 (growth differentiation factor) and TWSG 1 (twisted 
gastrulation factor) are candidate molecules released by the bone 
marrow that could mediate this effect (Hentze et al, 2010).  
 
                 Figure 9: Erythroid regulation of hepcidin 
 
                                 Source: Hentze et al, 2010. 
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3. Role of inflammatory cytokines in regulation of  
    hepcidin 
 
The inflammatory cytokine, interleukin-6 (IL6) activates JAK/STAT 
(JAK-Janus kinase; STAT- signal transducer and activator of 
transcription). STAT 3 activates the hepcidin promoter by binding to 
the STAT-binding motif close to the hepcidin transcription start site 
and up-regulates its expression (Nemeth et al. 2004). BMP 
signalling is also activated in response to inflammation  via SMAD4 
(Wang et al. 2005) and up-regulates hepcidin expression. 
 
  Figure 10: Regulation of hepcidin by inflammatory cytokine 
 
 
Source: Hentze et al, 2010. 
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4. Role of hypoxia in regulation of hepcidin 
  
Erythropoietin produced in response to hypoxia activates 
erythropoiesis. This, in turn, suppresses hepcidin.  
 
Role of hepcidin in iron-related disorders 
 
Iron-related disorders are mainly due to iron over-load and iron 
deficiency. It was observed that disorders with iron over- load are 
commonly associated with hepcidin deficiency or  resistance to 
hepcidin action (Ganz et al, 2011). Hereditary hemochromatosis is a 
genetic disorder associated with iron metabolism (Longo et al. 
2011). This genetic disorder is associated with mutation in Hfe gene. 
Juvenile form of hemochromatosis is mainly associated with non-
Hfe gene mutations (mutation in hemojuvelin and hepcidin genes). 
In adults with hemochromatosis, hepcidin synthesis is partially 
responsive to iron overload. Inappropriate levels of hepcidin were 
observed with iron over-load. Conventional treatment for 
hemochromatosis, venisection reduces the iron  levels in circulation 
and cause hepcidin deficiency ( Spasic V et al. 2007). 
 
In β-thalassemia, the expansion of erythroid precursors is observed 
mainly in the bone marrow.  The defect in β-globin production in 
erythroid precursors leads to excess α-chains. This excess α-chain 
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will precipitate that leads to the apoptosis of erythroid precursors in 
the marrow. The increase in erythropoietin production due to 
anemia leads to massive ineffective erythropoiesis which causes 
suppression of hepcidin leading to increased iron absorption(Tanno 
et al. 2007; Tanno et al. 2009). 
 
A genetic disorder, iron-refractory iron deficiency anemia (IRIDA), 
due to mutations in a negative regulator of hepcidin, the membrane 
protease matriptase-2 (also called TMPRSS6 - transmembrane 
protease serine 6) which cleaves HJV, reducing the phosphorylation 
of the SMAD complex  (Finberg et al. 2008; Du et al. 2008). This 
disorder is associated with over expression of hepcidin despite lower 
levels as in iron deficiency anemia 
 
Chronic inflammatory conditions such as infection, rheumatological 
disorders and inflammatory bowel disease are associated with iron 
deficiency anemia. In these conditions, anemia is partly due to 
increase in hepcidin levels by IL-6 stimulation (Ross et al. 2014).  
 
In chronic kidney disease, high levels of serum hepcidin levels were 
seen. Increased serum hepcidin levels were due to decrease in 
clearance or due to inflammation associated with the underlying 
disease and hemodialysis (Zaritsky et al. 2009). High levels of 
hepcidin lead to reduction in iron supply to erythroid precursors 
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leading to anemia and decreased responsiveness to erythropoietin 
therapy (Zaritsky et al. 2009). 
 
Anemia is a common manifestation of malignancy. Studies on 
anemia associated with Hodgkin’s disease and multiple myeloma 
has shown that features were similar to anemia of inflammation 
with high levels of hepcidin (Hohaus et al. 2010; Sharma et al. 
2008).  Increased hepcidin levels mainly due to inflammatory 
cytokines. 
 
Variation in hepcidin levels leads to change in the systemic iron 
levels. Increased hepcidin is associated with low serum iron levels, 
the iron supply to the erythroid bone marrow decrease leading to 
decreased heme synthesis. This reduction in heme synthesis 
manifests as anemia.  
 
Therapeutic implications of hepcidin   
 
Hepcidin levels are reduced in hereditary hemochromatosis and iron 
loading anemia  with inefficient erythropoiesis ( Spasic V et al. 
2007). Conventional treatment for hereditary hemochromatosis, 
phlebotomy is ineffective since it cause inappropriate decrease in 
hepcidin levels. 
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Therapeutic intervention with hepcidin antagonists can be 
considered in hereditary iron-refractory iron deficiency anemia. In 
this condition increased levels hepcidin is due to mutation in the 
membrane  protease matriptase-2 (also called TMPRSS6) (Finberg et 
al. 2008; Du et al. 2008), treatment with hepcidin antagonist can 
prevent resistance developed against oral iron supplementation .  
Anemia in chronic kidney disease is associated with elevated 
hepcidin levels. Treatment with hepcidin antagonist can be 
considered in the treatment for anemia in chronic kidney disease. 
 
 
PREGNANCY 
 
Pregnancy is a normal physiological process, which extends over a 
period of 280 days or 40 weeks from a woman’s last menstrual 
period to child birth. The period of 40 weeks is divided into first, 
second and third trimesters. Each trimester comprises a period of 
13 weeks  (Cunningham et al. 2014).  
 
Anemia in pregnancy due to increased iron demand 
 
Anemia in pregnancy is more common pathological state with a 
prevalence of 57.9 % in India. The Centre for Disease Control and 
Prevention, 1998 defines anemia in pregnant women who are on 
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iron supplementation as “hemoglobin (Hb) concentration of less 
than 11g/dl in the first and third trimesters and less than 10.5 g/dl 
in the second trimester”. “Post-partum anemia is defined as a 
hemoglobin concentration of less than 10 g/dl” (MMWR, 1998).  
 
Fall in hemoglobin levels occurs during pregnancy, the fall is mainly 
due to a disproportionate increase in plasma volume compared with 
that of red blood cell volume (Hytten, 1985). The increase in plasma 
volume is to meet the metabolic needs of an enlarged uterus, 
hypertrophied vasculature, developing placenta and fetus. 
Additional elemental iron (about 1000mg) is needed during 
pregnancy. Of this, 300mg is required for the fetus and placenta, 
200mg is lost through the gut, urine and skin and the remaining 
500mg compensates for the increase in total volume of erythrocytes 
(Cunningham et al. 2014). 
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                Figure11: Iron requirement during pregnancy  
 
                                 Source:  Bothwell TH, 2000      
 
Increased iron demands occur after 20 weeks of gestation; the 
requirement of iron is about 6-7mg/day (Bothwell 2000). The 
increase in iron requirement is almost doubled when compared with 
healthy non-pregnant females. This is mainly due to increases in 
maternal plasma volume. The maternal erythrocyte volume will not 
be adequate unless iron is supplemented therapeutically, since 
dietary supplementation and iron stores cannot meet this extra 
demand (Cunningham et al. 2014). Fetal hematopoiesis is usually 
not affected, since the placenta transfers iron to the fetal side, even 
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in conditions of maternal depletion and severe iron deficiency 
(Cunningham et al. 2014).  
 
Complications of anemia in pregnancy 
 
Anemia in pregnancy has deleterious effects on both the mother and 
fetus.  Maternal complications are based on the degree of anemia; 
this may range from an asymptomatic state to easy fatigability in 
mild anemia. In case of severe anemia, the mother can present with 
dyspnea, edema of dependent parts, shock, cardiac failure, toxemia 
of pregnancy and preterm labour (Smallwood, 1936). Fetal 
complications due to severe anemia in pregnancy include high 
neonatal mortality due to prematurity, still-births, low birth weight 
and delayed developmental milestones (Cunningham et al. 2014). 
 
Placenta as a unit for materno-fetal transfer of  
substances 
 
The placenta is the functional unit mainly involved in maternal-fetal 
transfer of nutrients and oxygen. The human placenta is 
hemochorial, even though maternal and fetal blood does not mix, 
exchange of nutrients and oxygen from mother to fetus occurs (Boyd 
et al.1970). Transport across the syncytiotrophoblast is 
bidirectional. 
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The decidua is a specially modified endometrium, which favours the 
function of the placenta (Cunningham et al. 2014).  According to the 
American College of Obstetricans and Gynecologists, pregnancy is 
established when implantation of the fertilized egg is complete (8-18 
days after fertilization) (Cunningham et al. 2014). The formation of 
the placenta starts as early as the morula stage of the embryo. The 
trophoectoderm which surrounds the morula differentiates into the 
trophoblast (Cunningham et al. 2014). The trophoblast plays an 
important role at the feto-maternal interface, till term of pregnancy. 
The chorion is a membrane surrounding the chorionic cavity 
around the embryo (Boyd et al. 1970). It is consists of trophoblast 
and mesenchymal tissue. Chorionic villi  are distributed over the 
entire periphery of the chorionic membrane (Boyd et al. 1970). 
 
The trophoblast is differentiated into an outer layer of 
syncytiotrophoblast and an inner layer of cytotrophoblast 
(Cunningham et al. 2014). The cytotrophoblast forms the germinal 
cells and secretory component of the placenta. The 
syncytiotrophoblast mainly helps in transport of nutrients and gas 
at the feto-maternal interface (Cunningham et al. 2014). 
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                       Figure 12: Placental transport of iron  
 
                             Source: Lipinski et al, 2013 
 
The transport of iron across the placenta is unidirectional 
(Contractor SF et al.1986). Dietary iron, iron stores in the mother 
and supplemented iron is delivered across placenta to meet the fetal 
demand. The maternal holo-transferrin binds to transferrin receptor 
1 (TfR 1) on the syncytiotrophoblast on the maternal side (McArdle 
et al. 1984; McArdle et al. 1985;Georgiff et al. 2000 ). The complex 
is internalized as endosome.  Iron is released from endosome via the 
DMT1 transporter (Georgiff et al. 2000). Iron transported out of 
syncytiotrophoblast to reach the fetal circulation via ferroportin on 
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the basolateral (fetal side) of syncytiotrophoblast (McKie et al. 2000; 
Abboud et al. 2000). Transferrin has high affinity for ferric (Fe 3+) 
iron. The ferrous iron is converted to ferric iron by a membrane-
bound copper oxidase (Danzeisen et al. 2002). Ferric iron released is 
taken up by fetal transferrin and enters fetal circulation for 
transport and iron uptake for development of fetus. 
 
Hepcidin levels in pregnancy 
 
In pregnancy, maternal hepcidin levels depend on the maternal iron 
status and fetal demand. Hepcidin is down-regulated when there is 
an increased tissue demand for iron. Evidence from animal studies 
suggests that hepcidin mRNA expression is decreased in maternal 
liver with iron deficiency and reversed by iron supplementation 
(Gambling et al. 2009). In the same study they have shown 
significant negative correlation between fetal hepatic iron levels and 
hepcidin levels both in mother and fetus.  Another study showed 
levels of maternal hepcidin  reduced in rats, as the pregnancy 
progresses to enable uptake of iron by the fetus; its level returned to 
normal levels post-partum (Millard et al. 2004).  
 
Transgenic mouse models which over-express hepcidin shows 
reduced levels of placental transferrin receptor 1 (TfR1), resulting in 
severe anemia and early death of offspring (Martin et al. 2004). 
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Another study done on pregnant women during the third trimester 
and in newborns suggests that maternal hepcidin and iron status in 
the mother and fetus play important roles in placental transfer of 
iron (Young et al, 2011). In the same study, it was also reported that 
heme iron in the diet is absorbed better than non-heme iron; this 
heme-iron uptake occurs mainly in the third trimester of pregnancy 
(Young et al, 2011).   
 
Hepcidin is positively correlated with ferritin suggesting there was 
depletion of iron stores and low hepcidin levels enable the transfer 
of iron to the fetus. Hepcidin was negatively correlated with 
erythropoietin, a marker of erythropoiesis in pregnancy (Finkenstedt 
et al. 2012). Fetal hepcidin levels regulate ferroportin on the baso-
lateral side of syncytiotrophoblast to meet the fetal iron demand 
(Donovan et al. 2000).  
 
A meta-analysis was recently published by Koenig et al. 2014 on 
hepcidin and its role in pregnancy. Their searches revealed only 10 
human and 6 animal studies on this, showing limited nature of 
literature in this area. Of the human studies, 6 were cross-sectional 
designs and 4 were longitudinal studies. This shows the literature 
in this area is limited and no studies were from Indian population, 
where the prevalence of anemia in pregnancy is higher. In the 
review by Koenig et al. (2014), they found maternal serum hepcidin 
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levels correlated with various hematological indices and markers of 
iron status from Rehu et al. 2010; Schultze et al. 2008; van Santen 
et al. 2013. This suggested that well-known biological relationship 
linking iron indices, hepcidin and erythropoiesis was operational in 
pregnancy as well. As shown Young et al, 2011 the maternal 
hepcidin and iron status in the mother and fetus (done by cord 
blood analysis at the time of delivery) play important roles in 
placental transfer of iron (Koenig et al. 2014). 
 
In summary, pregnancy is known to be associated with increased 
iron demand to provide adequate iron for fetal development. 
Evidence from animal studies also showed that maternal hepcidin 
levels are decreased during pregnancy. This would be expected to 
enhance release of iron from maternal stores and increase maternal 
intestinal iron absorption, which in turn would result in increased 
transfer of iron to the fetus. However, human studies in this area 
are limited. In addition, there is no data available from Indian 
populations, where the prevalence of anemia in pregnancy is high, 
regarding hepcidin levels during pregnancy.  We therefore designed 
a cross-sectional study to estimate serum hepcidin levels in the 
first, second and third trimesters of normal pregnancy and in age-
mated non-pregnant women. We also aimed to correlate hepcidin 
levels with hematological parameters and serum ferritin, a marker 
of iron stores. 
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THE STUDY 
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Background of the study 
 
Iron requirements increase during pregnancy. Hepcidin, a peptide 
hormone produced in the liver is the major regulator of normal iron 
homeostasis. Evidence from animal studies shows that hepcidin 
levels are reduced throughout pregnancy and then raised in the post-
partum to provide adequate iron for fetal development. Literature in 
this area on human subjects is very limited. 
 
Objective of the study 
 
The aim and objective of this cross-sectional study was to determine 
the serum hepcidin levels in subjects without any complication of 
pregnancies and to correlate it with hematological parameters and 
ferritin.  
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MATERIALS 
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Equipments used 
 
1. Elix and Milli-Q ultrapure water systems (Millipore, USA)  
2. Table-top refrigerated centrifuge (MPW R 350, MPW, Poland)  
3. Micro plate reader (Model 680, Bio-Rad Laboratories, Inc, UK) 
 
Chemicals and reagents used for estimation of  
hepcidin 
 
The chemicals and reagents provided by Peninsula Laboratories 
(Bachem Group, San Carlos, USA) for estimation of hepcidin were: 
1. Standard diluent (peptide-free human serum) 
2. Lyophilized standard, anti-serum against hepcidin, biotinylated 
peptide  
3. Enzyme immune-assay buffer, streptavidin- horseradish 
peroxidase (HRP), substrate solution (TMB - 3, 3′, 5, 5′-
Tetramethylbenzidine solution) and stop solution (2N HCl).  
 
Miscellaneous consumables used 
 
1. Vacutainer blood collection tubes (BD Biosciences, Plymouth, 
UK).  
2. Micro-tubes and centrifuge tubes (15ml) (Tarsons Products 
Private limited, Kolkata, India).   
3. Micro tips (Tarsons Products Private limited, Kolkata, India).   
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The study was approved by the Institutional Review Board (IRB) at 
Christian Medical College (CMC), Vellore, India (IRB Min. No. 8151 
dated 09.01.2013). 
                                                     
                                 SUBJECTS 
 
Women with uncomplicated pregnancy, who attended the antenatal 
clinic at the Community Health and Development centre (CHAD) 
Hospital in CMC, Vellore, were recruited.  
 
Inclusion criteria: 
 
Pregnant women with 
1. Hemoglobin levels equal to or more than 11 gm/dL in the first and 
third trimesters and more than 10.5 gm/dL in the second trimester  
2. Serum levels of C-reactive protein (CRP) less than 6 mg/dL    
 
Exclusion criteria: 
 
Pregnant women with  
1. Hemoglobin levels less than 11 gm/dL in first or third trimesters 
or less than 10.5 gm/dL in the second trimester.  
2. Serum levels of C-reactive protein (CRP) more than 6 mg/dL 
57 
 
3. Any complication of pregnancy 
4. Those who were not willing to participate in the study 
 
The pregnant women were recruited into the study on their first 
antenatal visit.  None of them were on iron supplements as far as 
was ascertainable. Control subjects were non-pregnant women staff 
of the pre-clinical departments at CMC, Vellore. They were between 
25 and 30 years of age.  
 
INFORMED CONSENT 
 
Once pregnant women and control subjects were identified on the 
basis of the inclusion and exclusion criteria listed above, they were 
told about the study and invited to participate. They were provided 
with an information sheet in either Tamil or English, depending on 
their preference. Once they indicated their willingness to 
participate, written informed consent was obtained from them. 
Clinical and socio-demographic information of the subjects was 
obtained in the proforma used (Appendix 2). Information sheet and 
informed consent form in English which was used is attached in 
Appendix 3. 
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Group 
   No. of  
participants 
Site of recruitment 
Non-pregnant 
control women 
10 Preclinical departments of CMC, 
Vellore 
Pregnant 
women in their 
first trimester 
10 CHAD hospital (antenatal clinic) 
Pregnant 
women in their 
second 
trimester 
10 CHAD hospital (antenatal clinic) 
Pregnant 
women in their 
third trimester 
10 CHAD hospital (antenatal clinic) 
                                 
 
CALCULATION OF SAMPLE SIZE 
 
The sample size calculation was done based on the study 
Finkenstedt et al, 2012.  
 
The mean difference of the hepcidin levels between first and third 
trimester in this study was 6.5 ng/ml. The standard deviation of the 
hepcidin level was taken as 9 ng/ml. The sample size calculation 
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was done, using the formula below, with 80% power and 5% level of 
significance. 
 
 
Formula:  
  
           
     
  
 
 
Z α/2 is the 5% level of significance -1.96 
Z 1-β   is 80% power - 0.84 
s – Standard deviation (9 ng/ml) 
d – Mean difference (6.5ng/ml) 
 
Since the money allocated for a fluid research grant for post 
graduate dissertation was only Rs. 80,000 for 2 years, it was 
possible only to estimate only 40 samples with the reagents that 
were purchased with this amount. Hence, only 40 patients were 
studied. This included 10 in each trimester and 10 non-pregnant 
controls.  
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SAMPLE COLLLECTION 
 
Samples were collected from the subjects by venipuncture using BD 
vacutainer tubes.  Approximately 6ml of blood was collected from 
each subject and control.  
 
Processing of samples 
 
The blood collected was used to estimate hemoglobin and to obtain 
serum. For the latter, clotted blood in the tubes was centrifuged at 
2500 rpm, within 2 hour of blood collection. Serum was separated 
and divided into 4 aliquots.  Additional values of hematological 
parameters of the subjects (Hematocrit and Mean Corpuscular 
Volume [MCV]) were obtained from the hospital records of the 
patients, when available. 
Storage of samples 
 
Serum samples were stored at -70°C. They were used for estimation 
of serum hepcidin, CRP (C-reactive protein) and ferritin. 
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ESTIMATION OF SERUM HEPCIDIN 
 
Reagents for the estimation were purchased from Peninsula 
Laboratories, (Bachem Group, San Carlos, USA). 
 
Principle of the method 
 
The method used was based on competitive immunoassay. The anti-
rabbit antiserum against hepcidin-25   was captured on an antibody 
(anti- rabbit antibody) coated on a 96-well plate. A fixed 
concentration of biotinylated tracer (Bt-tracer) and varying 
concentrations of the standard or the peptide in diluted serum 
sample competed for binding to the anti-serum. The captured Bt-
tracer was subsequently bound by streptavidin-conjugated 
horseradish peroxidase (SA-HRP), which produced a colored product 
when substrate was added. 
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           Competitive enzyme immuno assay for serum hepcidin 
 
 
 
Components in the kit 
 
1. 96-well coated plate. 
2. Enzyme immunoassay buffer (50ml). 
3. Standard lyophilized hepcidin peptide (1μg). 
4. Standard diluents (8ml) (Peptide-free human serum) 
5. Antiserum against hepcidin-25 (Lyophilized powder) 
6. Lyophilized powder of biotinylated peptide 
7. Streptavidin-HRP -100μl (HRP - horse radish peroxidase) 
8. Substrate solution (TMB- 3, 3’, 5, 5’-tetramethylbenzidine) (11ml 
of TMB and hydrogen peroxide [H2O2]) 
9. Stop solution – 2N HCl (hydrochloric acid, 15ml) 
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As per manufacturer’s information, standard diluent, lyophilized 
standard, antiserum and biotinylated peptide were stored at -20°C. 
Enzyme immunoassay buffer, streptavidin-HRP, substrate solution 
and stop solution were stored in a refrigerator (2-4°C). These 
reagents were stable for one year, under these conditions.  
 
Preparation of the reagents 
 
The unopened kit and reagents were equilibrated to room 
temperature before preparation of samples and working reagents. 
 
1. Stock standard: To 1μg of lyophilized standard, 1ml of standard 
diluent was added and mixed, using a vortex mixer. 
 
Standard ng/ml Range: 0.02-25 ng/ml 
Stock 1000  
S1 25.00 Added 5 μl stock  + 195 μl diluent  
S2 6.25 Added 40 μl S1 + 120 μl diluent  
S3 1.56 Added 40 μl  S2 + 120 μl diluent  
S4 0.39 Added 40 μl  S3 + 120 μl diluent  
S5 0.10 Added 40 μl   S4+ 120 μl diluent  
S6 0.02 Added 40 μl  S5+ 120 μl diluent 
S0 0.00   120 μl diluent 
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2. Samples: The 40 samples in the study were diluted 1 in 10 (12 μl 
of sample + 108 μl of standard diluent) 
 
3. Enzyme immuno assay buffer (EIA buffer): EIA buffer (50ml) was 
diluted to 1,000 ml with sterile deionized water (18 MOhm) and 
mixed well. 
 
4. Antiserum: 5ml of EIA buffer was added to the lyophilized 
antiserum and mixed, using a vortex mixer. 
 
5. Biotinylated-tracer (Bt-tracer): 5ml of EIA buffer was added to the 
lyophilized powder of Bt- tracer. 
 
6. Streptavidin-HRP: The tube was centrifuged before dilution. It 
was diluted 1 in 200 with EIA buffer (60 μl of streptavidin-HRP with 
12ml of EIA buffer) and mixed, using a vortex mixer. 
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       Layout of 96-well micro titre plate used in the study 
 
         B- Blank; S- standards; T- unknown samples 
Procedure 
 
Step 1: Added 25 μl of antiserum to each well and 25 μl of EIA  
           buffer to the blank well.  Incubated at room temperature for   
           1 hour. 
 
Step 2: Added 50 μl of diluted standard/ sample to each well and 
           50 μl of diluent in the blank well. Incubated at room    
           temperature for 2 hours. 
 
Step 3: Rehydrated biotinylated-tracer (Bt-tracer) with EIA buffer  
           and added 25 μl of Bt-tracer per well. 
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Step 4: Sealed the micro-plate and incubated at 4°C in refrigerator  
           overnight.  
 
Step 5:Re-equilibrated the micro titer plate to room temperature. 
 
Step 6: Washed the immunoplate 5 times with 300 μl of EIA buffer  
            per well. 
 
Step 7: Added 100 μl per well of streptavidin-HRP to all the wells. 
            Incubated at room temperature for 1 hour. 
 
Step 8: Washed the immunoplate 5 times with 300 μl of EIA buffer  
            per well. 
 
Step 9: Added 100 μl of TMB (substrate solution) per well.  
            Incubated at room temperature for 30-60 minutes. 
 
Step 10: Readings were taken at 650nm, during development of  
              blue colour  
 
Step 11: Terminated the reaction with 100 μl of 2N HCl per well.   
 
Step 12: Readings were taken at 450 nm, within 10 minutes of  
              termination 
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Readings of optical density (OD) were obtained, using the software 
micro plate manager of the ELISA plate reader. . 
 
       Image of microtitre plate after termination of the reaction 
 
 
 
                    
A standard curve was plotted on a semi-log scale, using Microsoft 
Office Excel, 2007. The mean of the OD readings was used for the y 
axis and the concentrations of the standards (ng/ml) for the x axis. 
The serum hepcidin levels were calculated using four parameters 
logistic regression analysis using the following formula. 
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This equation was used to calculate the value of fit and plot 
“smooth line of fit”. The four parameters a (maximum), b (slope), 
c (IC50, point of inflection), and d (minimum) were adjusted, till the 
value of fit was satisfied and the fit was good. 
 
                            
 
This equation was used to calculate the concentrations of samples, 
expressed in ng/ml. 
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ESTIMATION OF SERUM C-REACTIVE PROTEIN 
 
CRP levels were estimated in Department of Clinical Microbiology, 
CMC, Vellore. 
 
Instrument used 
 
Reagents and equipment used for serum CRP analysis were 
manufactured by Siemens GmbH, Marburg, Germany. The 
nephelometer used was BN Prospec, Siemens GmbH, Marburg, 
Germany. 
 
Principle of the method (particle-enhanced nephelometry) 
 
Polystyrene particles coated with monoclonal antibodies specific to 
human CRP aggregated when mixed with samples containing CRP. 
A beam of light passed through the aggregates was scattered. The 
intensity of the scattered light was proportional to the concentration 
of the relevant protein in the sample. The result was evaluated by 
comparison with a standard of known concentration. 
 
Estimation of serum CRP for samples from both subjects (about 39 
samples) and controls (about 12 samples) was done. Eleven samples 
were excluded from the study, as the serum CRP levels in these 
samples were more than 6mg/dl. 
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                    ESTIMATION OF SERUM FERRITIN 
 
Estimation of serum ferritin was done in the Department of Clinical 
Biochemistry, CMC, Vellore. 
 
Analyzer used 
 
Siemens, ADVIA Centaur system Xpi, UK. 
 
Principle of the method (two-site sandwich immunoassay using 
direct chemiluminescence technology) 
 
Two anti-ferritin antibodies were used in this method. The first 
antibody was a polyclonal goat anti-ferritin antibody. This antibody 
was labelled with acridinium ester. The second antibody was a 
monoclonal mouse anti-ferritin antibody. The second antibody was 
in the solid phase that was covalently coupled with paramagnetic 
particles. The amount of ferritin present in the patient’s sample was 
directly proportional the amount of relative light units detected by 
the system. 
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DATA ANALYSIS 
 
The Statistical Package for the Social Sciences (SPSS) software 
package, version 16, was used to analyze the data obtained.  Data 
were subjected to Shapiro-Wilk test to check for normal 
distribution.  Values for serum hepcidin, ferritin and CRP were not 
normally distributed whereas hematological parameters 
(hemoglobin, hematocrit and mean corpuscular volume) were 
normally distributed. Data for hepcidin, ferritin and CRP were 
analyzed by Kruskal-Wallis test and pair-wise comparison was done 
using Mann-Whitney test. Hematological parameters were analyzed 
by Analysis Of Variance (ANOVA).  
 
Correlation analysis was done using Pearson’s correlation for 
normally distributed data and Spearman’s rank test for skewed 
data. Microsoft Office Excel 2007 was used for plotting standard 
curve fit and regression analysis for hepcidin against gestational 
age. A p value of <0.05 was considered as statistically significant in 
all cases. 
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RESULTS 
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Characteristics of subjects: 
 
Thirty pregnant women, with uncomplicated pregnancies, and ten 
non-pregnant women, in the reproductive age group, were the 
subjects of the study. Ten subjects were recruited in each of the 3 
trimesters of pregnancy; those at less than 13 weeks of gestation 
were considered to be in their first trimester, those between 13 and 
26 weeks of gestation were considered to be in the second trimester 
and those with gestational age greater than 26 weeks were 
considered to be in the third trimester. Ten non-pregnant females, 
as described earlier in the methodology section, served as control 
subjects for the study. The clinical characteristics of the subjects in 
the different groups are shown in Table 1.  
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Table 1- Clinical characteristics of subjects 
 
Parameters Controls First 
trimester 
Second 
trimester 
Third  
trimester 
 
Number of Subjects 
  
Age (years)  
(+ SD) 
 
 
10 
 
28.10  
(2.28)  
 
10 
 
22.20  
(3.39) 
 
10 
 
22.20 
 (1.84) 
 
10 
 
21.70  
(1.64) 
 
Mean gestational 
age (weeks+days) 
 (+ SD) 
 
Parity 
 9+1 
(2+1 ) 
18+2 
(4) 
 
30+6 
(4) 
Primi - 9 9 9 
Second pregnancy - 1 1 1 
 
Height (cm) 
(+ SD) 
 
160.8 
(2.82) 
153.4 
(3.50) 
156 
(6.36) 
152 
(6.97) 
Weight (kg) 
(+ SD) 
 
62.6 
(10.29) 
53.95 
(6.44) 
57.5 
(9.14) 
58.3 
(9.88) 
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Table 1- Clinical characteristics of subjects (cont’d) 
 
Parameters Controls First 
trimester 
Second 
trimester 
Third  
trimester 
 
Systolic blood 
 pressure 
(mmHg) (+ SD) 
 
 
115.4 
(6.04) 
 
110.8 
(7.08) 
 
107.1 
(12.77) 
 
106.5 
(9.14) 
Diastolic blood 
 pressure 
(mmHg) (+ SD) 
 
72.2 
(5.99) 
66.6 
(9.75) 
64 
(10.20) 
64.5 
(12.39) 
 
Data were shown as means (+ SD) 
 
Hematological parameters  
 
The hematological indices measured were hemoglobin, mean 
corpuscular volume (MCV) and hematocrit. These parameters were 
found to be normally distributed. 
 
Figures 1, 2 and 3 shows the means of these parameters in the 
subjects studied. 
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                           Figure 1. Hemoglobin levels in subjects 
 
Data were analyzed by ANOVA. * p < 0.05, when compared with 
control data.  
 
Hemoglobin levels showed a tendency to decrease with increasing 
gestational age. Levels in subjects in the third trimester were 
significantly lower than those of subjects in the control group. 
Values in the three trimesters did not differ significantly from one 
another.    
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Figure 2. Hematocrit levels in subjects 
 
  
Data were analyzed by ANOVA. 
 
The hematocrit values in the 3 groups of pregnant subjects were 
lower than that in the control group; these decreases were, however, 
not statistically significant. Values in the three trimesters did not 
differ significantly from one another. 
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                    Figure 3. Mean corpuscular volumes in subjects 
.  
 Data were analyzed by ANOVA. 
 
 
The MCV in the groups studied were not significantly different from 
one another.  
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Serum ferritin 
 
Serum ferritin was measured as a marker of iron status. The values 
of this parameter were found to have a skewed distribution.  The 
median values of ferritin in the 4 groups are shown in Figure 4. 
 
                                  Figure 4: Ferritin levels in subjects  
 
 
Data are shown as box and whisker plots, showing quartiles and 
medians. Analysis of data was done using Kruskal-Wallis test. 
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Serum ferritin levels were lower in the pregnant subjects than in the 
control group.  These decreases were, however, not statistically 
significant. Values in the three trimesters did not differ significantly 
from one another. 
 
 Serum C-reactive protein  
 
Serum C-reactive protein (CRP), a marker of inflammation, was 
estimated in the subjects of the study. Only subjects with CRP less 
than 6 mg/L were included in the study. The values obtained for 
serum CRP were found to have a skewed distribution.  
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                 Figure 5. Serum CRP levels in subjects 
 
 
Data are shown as medians. The range of values for each group is 
as follows: Controls (3.45 - 4.85); first trimester (3.45 - 5.71); 
second trimester (3.45 - 5.59); third trimester (3.45 - 3.45). Analysis 
of data was carried out using Kruskal-Wallis test.  
 
There were no significant differences in the values for CRP among 
the groups studied. 
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Serum hepcidin levels  
 
Serum hepcidin was measured by ELISA, using a commercially 
available kit (Bachem Group, San Carlos, USA). A standard curve 
was plotted on a semi-log scale, using Microsoft Office Excel 2007. 
The concentrations of the standards (ng/ml) were used for the x 
axis; the mean of the optical density (OD) readings obtained for each 
standard was used for the y axis.  
 
The standard curve generated is shown in Figure 6. Concentrations 
of hepcidin levels in each sample were calculated from this curve.  
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Figure 6: Standard curve for hepcidin 
 
 
 
Values for serum hepcidin levels in the patients’ samples were not 
normally distributed. The median values of hepcidin in the groups 
are shown in Figure 7.  
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Figure 7:  Serum hepcidin levels in subjects 
 
 
 
Data are shown as box and whisker plots, showing quartiles and 
medians. Analysis of data was done using Kruskal-Wallis test. 
  
Median hepcidin levels in pregnant subjects were found to be lower 
than in control subjects. They showed a tendency to decrease with 
increasing gestational age. The decreases were, however, not 
statistically significant.  
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Serum hepcidin levels in pregnant subjects were plotted against 
their gestational ages by regression analysis with Microsoft Office 
Excel 2007.                     
         
       Figure 8: Serum hepcidin levels versus gestational age 
 
 
 
Serum hepcidin levels showed a trend to decrease with increases in 
gestational age    
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Table 2: Correlation analysis for normally distributed variables 
 
    Correlation  r-value p-value 
 
All subjects (non-pregnant and 
pregnant subjects) 
  
Hemoglobin vs hematocrit 0.906 0.000 
Non-pregnant subjects   
Hemoglobin vs hematocrit 0.906 0.000 
Pregnant subjects   
Hemoglobin vs hematocrit 0.906 0.000 
First trimester   
Hemoglobin vs hematocrit 0.910 0.000 
Second trimester   
Hemoglobin vs hematocrit 0.910 0.000 
Third trimester   
Hemoglobin vs hematocrit 0.905 0.000 
 
Data were analyzed by Pearson correlation coefficient. 
 
Hemoglobin correlated positively with hematocrit values in non-
pregnant subjects, in pregnant women in all three trimesters and 
also in the total combined group of pregnant and non-pregnant 
subjects. 
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Table 3: Correlation analysis for data with skewed distributions  
 
    Correlation  r-value p-value 
 
All subjects (non-pregnant 
and pregnant subjects) 
  
Ferritin    
    vs hemoglobin 0.384* 0.015 
    vs hematocrit 0.282 0.077 
    vs MCV 0.305 0.056 
Hepcidin vs MCV -0.300 0.060 
Non-pregnant subjects    
Ferritin vs MCV 0.636* 0.048 
All pregnant subjects   
Hemoglobin vs gestational age -0.353* 0.026 
First trimester   
Ferritin vs hemoglobin 0.723* 0.018 
vs hematocrit 0.624 0.054 
Hepcidin vs MCV -0.673* 0.033 
Third trimester   
Ferritin vs hemoglobin 0.646* 0.043 
 
Data were analyzed by Spearman’s correlation coefficient. 
*p < 0.05 
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Various significant correlations were seen among the data with 
skewed distribution. When the total data, from both non-pregnant 
and pregnant subjects, were analysed, a significant positive 
correlation was found between ferritin and hemoglobin; there was 
also a tendency for a similar relationship between ferritin and 
haematocrit and MCV.  In this group, there was also a tendency for 
serum hepcidin and MCV to be negatively correlated.  
 
When non-pregnant subjects were considered alone, ferritin levels 
and MCV correlated positively with one another. Among pregnant 
women, hemoglobin levels negatively correlated with gestational age. 
Positive correlations were found between ferritin and hemoglobin in 
the first and third trimesters and with haematocrit in the first 
trimester. Hepcidin and MCV levels correlated negatively in the first 
trimester.  
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Summary of findings 
 
1. Hemoglobin levels were lower in pregnant women than in non-
pregnant ones, with the decrease being significantly lower in women 
in the third trimester.  
 
2. Values for hematocrit and mean corpuscular volume in the 3 
groups of pregnant women tended to be lower than those in the 
control group, but not significantly so. 
 
3. Serum ferritin levels tended to be lower in the pregnant women 
than in non-pregnant women, but not significantly so. 
 
4. Serum hepcidin levels were found to fall with increasing 
gestational age, but were not significantly different in the groups 
studied. 
 
5. Hemoglobin correlated positively with hematocrit and ferritin 
levels in both non-pregnant and pregnant women. 
 
6. Hepcidin correlated negatively with mean corpuscular volume in 
the first trimester; there was a tendency to the same correlation in 
the combined group of non-pregnant and pregnant women as well.      
 
90 
 
 
 
 
                   
 
 
 
 
 
 
 
 
 
DISCUSSION 
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Knowledge about mechanisms involved in iron homeostasis has 
progressed tremendously in the last 2 decades. The discovery of 
proteins involved in these processes has helped to better 
understand disorders related to iron metabolism (Andrews and 
Schmidt 2007).  
 
Hepcidin is the major regulatory hormone that maintains systemic 
iron levels (Murray et al. 2012). It is regulated by many processes; 
erythropoiesis and hypoxia cause it to be down-regulated (Nicolas et 
al. 2002), while inflammation and iron overload cause it to be up-
regulated (Nemeth et al. 2004; Pigeon et al. 2001).  
 
Pregnancy is associated with apparently decreased maternal serum 
iron levels; this is due to hemodilution and also due to increased 
demands for iron by the fetus (Cunningham et al. 2014). The 
increase in plasma volume in pregnancy, which is essential to meet 
the metabolic needs of an enlarged uterus, hypertrophied 
vasculature, developing placenta and the fetus, is responsible for 
hemodilution.  
 
In pregnancy, an increased rate of erythropoiesis is required for fetal 
development and this may lead to down-regulation of hepcidin. 
About 1000 mg of elemental iron is needed during pregnancy; this 
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exceeds normal iron stores in females (Longo et al. 2011).  It is 
expected that maternal hepcidin levels would be down-regulated in 
pregnancy to provide more iron to the placenta, for transfer to the 
fetus. 
 
 Iron is transported across the placenta through ferroportin, which 
is located on the baso-lateral side of the syncytiotrophoblast 
(Donovan et al. 2000). Ferroportin at this site is regulated by fetal 
hepcidin (Donovan et al. 2000). Both maternal and fetal hepcidin 
levels determine the transfer of iron across the placenta. A previous 
study has shown that cord blood hepcidin levels did not correlate 
with markers of maternal iron status, but correlated well with 
markers of iron status in the fetus  (Rehu et al. 2010). Another 
study done on pregnant women, in their third trimester and in 
newborns, suggests that maternal hepcidin and iron status in the 
mother and fetus play important roles in placental transfer of iron 
(Young et al, 2011).  
 
Hepcidin has been shown to be down-regulated as pregnancy 
progresses, in keeping with increased iron demands (Finkenstedt et 
al. 2012) . In the same study, the authors have reported a negative 
correlation between serum levels of hepcidin and erythropoietin. A 
study by van Santen et al (2013) has shown that hepcidin levels 
were decreased in the second and third trimesters and increased in 
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the post-partum period. This has also been reported by Gyarmati et 
al. (2011); however, the increases seen did not correlate with serum 
iron and ferritin levels. Studies on rats have also shown that 
maternal hepcidin levels fell as pregnancy progressed; these 
returned to normal levels in the post-partum period (Millard et al. 
2004).  
 
In the present cross-sectional study, serum hepcidin levels showed 
a trend to decrease with increasing gestational age. The falls seen 
were, however, not statistically significant. The non-significant 
nature of the change may be accounted for by the small sample size 
in the study. Decreases in serum hepcidin levels with progression of 
pregnancy have also been reported by others, with lowest levels 
reported in the third trimester (Finkenstedt et al. 2012; van Santen 
et al 2013; Dao et al. 2013). Hemo-dilution may be a factor that 
contributes to such a decrease. Another factor is likely to be 
increased iron demands by the fetus. With increasing gestational 
age, fetal requirements for iron increase. Hepcidin levels would need 
to be down-regulated to meet such increased requirements 
(Blackburn, 2003). Animal studies have also documented decreased 
hepcidin expression with progression of pregnancy and increases 
post-partum (Millard et al. 2004, Cornock et al, 2013).However, it is 
not known what specifically regulates hepcidin levels in pregnancy 
(Koenig et al, 2014).  
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Estimation of serum hepcidin levels have been done by different 
methods. These include mass spectrometry, cation exchange 
chromatography and enzyme linked immunosorbent assay for 
different studies (Finkenstedt et al. 2012; van Santen et al. 2013; 
Dao et al. 2013). In the present study a commercially available 
ELISA kit was used for estimation of serum hepcidin levels. The 
median hepcidin levels in the present study are similar to those 
reported by Finkenstedt et al. (2012) in pregnant women, even 
though the methods of estimations differ. It is often difficult to make 
direct comparison of serum hepcidin levels when estimations have 
been done by different methods (Koenig et al. 2014). Comparison of 
hepcidin levels would be easier if reference interval at different 
stages of pregnancy was known (Koenig et al. 2014). 
 
Koenig et al. (2014) have carried out a meta-analysis of publications 
that have studied hepcidin in pregnancy. Their searches revealed 
only 10 human and 6 animal studies on this, showing limited 
nature of literature in this area. Of the human studies, 6 were 
cross-sectional designs and 4 were longitudinal studies. None were 
done on Indian populations. Sample size in these studies varied 
from as little as 19 to as many as 191 and included those done at 
various time points during pregnancy and also in the post-partum 
period. The methods used for estimation included mass 
spectrometry and ELISA. The authors concluded that it is difficult 
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to make direct comparisons among the various estimations done 
because of a lack of standardization of the methods used. Reference 
ranges for hepcidin levels in pregnancy are not available and need 
to be established (Koenig et al, 2014).  
 
Maternal serum hepcidin levels have been shown to correlate with 
various hematological indices and markers of iron status (Rehu et 
al. 2010; Schultze et al. 2008; van Santen et al. 2013). This 
suggested that the well-known biological relationship linking iron 
indices, hepcidin and erythropoiesis was operational in pregnancy 
as well. The present study showed a correlation only between serum 
hepcidin and MCV, but not the other hematological parameters and 
indices of iron status. This may be the reflection of small sample 
size in the study. In the post-partum period, hepcidin levels have 
been shown to rise; however at this point, it did not correlate with 
markers of iron status (Rehu et al. 2010; Schultze et al. 2008; van 
Santen et al. 2013). 
 
Inflammation is known to cause up-regulation of  hepcidin 
transcription (Nemeth et al. 2004). Because of this, it was necessary 
to rule out the presence of inflammation in the subjects. In order to 
do this, only subjects with serum C-reactive protein levels less than 
6 mg/L were recruited for the present study. Hence, it is certain 
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that inflammatory factors did not influence serum levels of hepcidin 
in these patients. 
 
Serum ferritin levels in pregnancy are affected by factors such as 
hemodilution and iron supplementation (Burtis et al. 2012). In 
pregnancy, it has been shown that transferrin saturation or a 
sTfR/ferritin ratio are better indicators of iron status than serum 
ferritin levels by themselves (Burtis et al. 2012).  Evidence from an 
earlier study has shown  positive correlations between serum levels 
of hepcidin and ferritin (Finkenstedt et al. 2012), suggesting that 
maternal iron stores get depleted during pregnancy, thus  causing 
hepcidin  to be down-regulated. A longitudinal study showed that 
serum hepcidin levels positively correlated with serum ferritin levels 
and transferrin saturation and negatively with soluble transferrin 
receptor throughout pregnancy; the correlation with ferritin was not 
seen 24 hours post-partum (van Santen  et al. 2013). Such a 
correlation was not seen in the present study, once again, probably 
due to the cross-sectional design of the study and the small sample 
size.  
 
In studies done on normal healthy, non-anemic pregnant women on 
iron supplementation, parameters of iron status, such as serum 
iron, transferrin saturation and ferritin levels, were found to 
decrease with the progression of pregnancy and increased after 
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delivery (Choi et al.  2000).  In the present study, ferritin levels were 
lower in pregnant subjects, when compared with control subjects. 
This may be explained by the fact that maternal iron stores get 
depleted in pregnancy. However, no correlation was found between 
serum levels of hepcidin and ferritin in the groups studied.  Once 
again, the small sample size of the present study may account for 
this. Larger numbers of subjects will need to be studied to further 
study these relationships.  
 
A recent study in Indian pregnant women showed no correlation 
between ferritin and red cell indices (Tiwari et al. 2013), unlike the 
one by Byg et al (2000). In the present study, ferritin levels in 
pregnant women correlated with hemoglobin levels; this observation 
is in keeping with the findings of Byg et al (2000).  One of the 
reasons for the lack of agreement with the findings of Tiwari et al 
may be the fact that none of the subjects of this study were anemic, 
as diagnosed by WHO criteria for anemia in pregnant women, while 
in the study by Tiwari et al, nearly 50% of the women had anemia. 
In the present study, ferritin also tended to be positively correlated 
with mean corpuscular volume, again in keeping with the findings 
of Byg et al (2000).  In the present study, hemoglobin levels 
significantly decreased in third trimester when compared with 
controls. The finding that hemoglobin decreased with increasing 
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gestational age is likely to be a result of hemodilution with 
significantly lower levels in the third trimester.  
 
The cross- sectional nature of the present study is a limitation. It 
would be best to carry out longitudinal studies to determine 
hepcidin levels in the course of pregnancy, as has been done by 
Simavli et al (2014). These authors have shown that elevated serum 
hepcidin levels were associated with adverse outcomes of 
pregnancy. It was not found that it was not possible to follow the 
patients in the study up to delivery to determine the outcome of 
pregnancy.  
 
Conclusion 
 
Serum hepcidin levels tended to decrease with increasing 
gestational age, but the decreases seen were not statistically 
significant. Since the sample size in this study was small, further 
studies in this area are warranted to confirm these findings and to 
further study the complex biological relationships between hepcidin 
and iron metabolism in pregnancy. 
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Limitations of the study 
 
1. The sample size for the study was small. A larger number of 
patients will need to be studied to elucidate more clearly the 
relationship between hepcidin and iron-related parameters in 
pregnant women.  
 
2.  It was not possible to assess the outcomes of pregnancy with 
regard to the status of the babies born. There were difficulties in 
obtaining information on gestational age at delivery of the subjects 
in the study (to determine whether the babies were born preterm, at 
term or post term) and weight of the babies (normal/low birth 
weight/ high birth weight). These limitations were due to an 
inability to trace the all the subjects at a later date to see if they had 
delivered at CHAD hospital.  
 
3. It was not possible to carry out cord blood analysis on the babies 
born to the subjects of the study. Such analyses would be useful to 
shed light on the complex relationships involved in handling of iron 
in pregnancy.  
   
4. It was difficult to obtain reliable information from the pregnant 
subjects about iron supplementation.  Women in the first trimester 
said they had been given some tablets from village health nurses 
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(VHN). These were assumed to be tablets of iron and folic acid, but 
there was no way to verify this. Women in the second and third 
trimesters stated that they had taken some such tablets earlier in 
their pregnancy but had not been taking them in the recent past. 
However, none of these facts could be verified for certain.  
 
5. It was not possible to study other relevant parameters such as 
transferrin saturation and serum levels of soluble transferrin 
receptor, due to financial constraints.  
 
6. A longitudinal study to determine serum levels of hepcidin over in 
the course of pregnancy would have been ideal. Such a study would 
have allowed for assessment of relationships of parameters of 
interest with outcomes of pregnancy.   
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Future directions 
 
Longitudinal studies to on iron-related parameters in the mother in 
the course of uncomplicated pregnancies, along with cord blood 
analysis, will be useful for a better understanding of iron 
metabolism in the mother and the fetus. Studies on iron-related 
proteins in the placenta in these patients would also be useful in 
this regard.  
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 Appendix 3: Patient information sheet and consent forms 
 
Title of study: Serum hepcidin levels in pregnancy 
Investigators: Gnanapraba P, Joe Varghese, Jasmine Prasad, 
Visalakshi Jeyaseelan, Molly Jacob 
  Departments: Department of Biochemistry, Christian Medical College, 
Bagayam, Vellore; CHAD Hospital, Christian Medical College, Bagayam, 
Vellore 
 
The Department of Biochemistry, Christian Medical College (CMC), Vellore 
in association with Community Health and Development (CHAD) Hospital, 
CMC, Vellore is carrying out a study to try to understand why pregnant 
women often become anemic.  Often anemia occurs in pregnancy because 
the body does not have adequate amounts of iron in the body. We have 
permission to conduct a study to measure various substances in blood 
that are associated with iron and the development of anemia. For this, we 
would like to request for a sample of blood (10 ml) from you. Taking this 
sample of blood from you will not cause you any foreseeable harm. The 
information that we get from these measurements will help us understand 
better the mechanisms involved in development of anemia in pregnancy. 
In turn, we hope that this will help in development of more effective ways 
to deal with the problem. You will not be directly benefitted by this study 
but your participation will help to acquire advance knowledge in this area 
of medicine. The blood sample we take will be used only for research 
purposes. If any sample remains after we complete this study, we would  
123 
 
 like to request you for permission to store the sample and to use it for 
future studies that we may conduct on anemia and pregnancy. All 
information that we collect from you will be kept strictly confidential. If 
you are not willing to participate in the study you are free to say so. 
Whether you are part of the study or not will not affect your treatment in 
CHAD hospital.   
Dr.Gnanapraba.P; Contact no: 09444091561. 
Dr. Molly Jacob: 04162284267 
Dr.Jasmine Prasad: 04162284207 
    
        INFORMED CONSENT FORM FOR SAMPLE OF BLOOD. 
 
Dr.Gnanapraba P. has explained to me the details of the study 
proposed and what part I have in it.  I have understood what she 
has told me. I am willing to participate in the study. I give consent 
for 10 ml of blood to be collected from me. I understand that this 
will not affect my health in any foreseeable manner. The blood 
sample collected will be used only for research purposes. If there is 
any sample remaining after this study is completed, I give 
permission for the sample to be stored and used for any related 
future studies.  
 
Signature/thumb impression of the subject                                                              
Signature of investigator                             Date 
